FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein with a large extracellular domain, is overexpressed in most prostate cancer cells, making it a suitable target for prostate cancer (PCa) imaging and therapy [1].